Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633353 | 0.87 | PIM1 (0.42) | BRD4 | |
| SCHEMBL1277566 | 0.87 | BRD4 (0.37) | BRD4ATAD2KDM4EALDH1A1GLA | |
| SCHEMBL1277565 | 0.87 | BRD4 (0.37) | BRD4ATAD2KDM4EALDH1A1GLA | |
| SCHEMBL1278173 | 0.84 | BRD4 (0.35) | BRD4ATAD2KDM4EALDH1A1GLA | |
| SCHEMBL1277687 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1GLA | |
| SCHEMBL1277688 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1GLA | |
| SCHEMBL3030442 | 0.75 | PIM1 (0.40) | BRD4ATAD2 | |
| SCHEMBL3030445 | 0.75 | PIM1 (0.40) | BRD4ATAD2 | |
| SCHEMBL1277557 | 0.74 | APEX1 (0.40) | KDM4EALDH1A1GLA | |
| SCHEMBL1277554 | 0.74 | APEX1 (0.40) | KDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GCK, GCKR, HK1 | BRD4 3674/4885ATAD2 2052/4885KDM4E 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.